leisure time -WSS

leisure time

author：explore 2025-09-04 22:01:13 - browse：776

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Lack of health data on LGBTQ+ people has serious consequences

WSS

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Why Talkspace is targeting Medicare, a tricky market

EQRx, failed developer of low

Vertex non

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Mega Millions pot grows to $1.25 billion after no winner

Wikipedia

leisure time

focus

Jerome Adams on the need for new antivirals for Covid

A new approach to psychiatric drug development

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Longer MASH drug regimen improved liver, Akero study finds

Heart attack and stroke risk calculators need revising

‘Oppenheimer’ and the risks of AI in health care

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Cancer drug shortages should be causing more outrage

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

focus

New safety details link Apellis eye drug to rare cases of blindness

Medicare drug price negotiation continues, as pharma counteroffers

Microsoft's Peter Lee: Generative AI could help doctors be more human

Families look for replacement for GSK asthma drug Flovent

What the airline industry can learn from medicine

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

leisure time

Wikipedia

focus

hotspot